贝伐珠单抗对结直肠癌和胰腺癌切除术后并发症的影响。

The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.

机构信息

Department of Surgery, Mount Sinai Hospital, University of Illinois at Chicago, Chicago, Illinois, USA.

出版信息

J Surg Oncol. 2010 Oct 1;102(5):539-42. doi: 10.1002/jso.21598.

PMID:20812264

Abstract

Bevacizumab (Avastin™; rhuMab VEGF), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has seen increased use in the perioperative treatment of colorectal and pancreatic cancer. Little is known, however, regarding its impact on surgical outcomes in patients undergoing resection. The objective of this review was to examine if the addition of bevacizumab to existing neoadjuvant regimens increases morbidity after cancer resection.

摘要

贝伐珠单抗（阿瓦斯汀™；重组人抗血管内皮生长因子单克隆抗体）是一种针对血管内皮生长因子（VEGF）的单克隆抗体，已在结直肠癌和胰腺癌的围手术期治疗中得到越来越多的应用。然而，关于其对接受切除术的患者手术结局的影响，知之甚少。本综述的目的是检查在现有的新辅助治疗方案中添加贝伐珠单抗是否会增加癌症切除术后的发病率。